Carboplatin and vinorelbine in advanced non-small cell lung cancer: A phase I/II study

Oncologist

Volumn 6, Issue SUPPL. 1, 2001, Pages 12-15

  Masters, Gregory ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b EVANSTON NORTHWESTERN HEALTHCARE   (United States)

Author keywords

Carboplatin; Dose limiting toxicity; Vinorelbine

Indexed keywords

CARBOPLATIN; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PERMISSIBLE DOSE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0035129546     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.6-suppl_1-12     Document Type: Conference Paper

References (14)

1. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: Results of a European multicenter trial including 612 patients
2. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer (NSCLC): A Southwest Oncology Group study
3. A randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in untreated advanced non-small cell lung cancer (NSCLC): A Southwest Oncology Group (SWOG) trial
4. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: A randomised trial
5. Single agent versus combination chemotherapy in patients with advanced non-small cell lung carcinoma
6. Vinorelbine and carboplatin for the treatment of patients with advanced NSCLC: A phase II response, toxicity and survival study
7. Vinorelbine (Navelbine)/carboplatin combination therapy: Dose intensification with granulocyte colony-stimulating factor
8. Efficacy and toxicity of vinorelbine-carboplatin combination in the treatment of advanced adenocarcinoma or large cell carcinoma of the lung
9. Carboplatin and vinorelbine in advanced non-small cell lung cancer
10. Phase I study of vinorelbine and carboplatin in advanced non-small cell lung cancer
11. A dose-escalating study of carboplatin combined with vinorelbine in non-small-cell lung cancer
12. Carboplatin and vinorelbine in the treatment of advanced non-small-cell lung cancer: A multicenter phase II study
13. "Carnavel" a retrospective experience with combination vinorelbine (VLB) and carboplatinum (carbo) in 35 patients with stage III/IV non-small-cell lung cancer (NSCLC)
14. A phase I/II study of vinorelbine (NAV) and carboplatin (CARB) for advanced non-small cell lung cancer (NSCLC)